Financials data is unavailable for this security.
View more
Year on year Gilead Sciences Inc had relatively flat revenues (27.28bn to 27.12bn), though the company grew net income 23.34% from 4.59bn to 5.66bn.
| Gross margin | 77.80% |
|---|---|
| Net profit margin | 0.40% |
| Operating margin | 2.90% |
| Return on assets | 0.19% |
|---|---|
| Return on equity | 0.62% |
| Return on investment | 0.24% |
More ▼
Cash flow in USDView more
In 2023, Gilead Sciences Inc increased its cash reserves by 12.44%, or 673.00m. The company earned 8.01bn from its operations for a Cash Flow Margin of 29.53%. In addition the company used 2.27bn on investing activities and also paid 5.13bn in financing cash flows.
| Cash flow per share | 2.30 |
|---|---|
| Price/Cash flow per share | 38.38 |
| Book value per share | 14.83 |
|---|---|
| Tangible book value per share | -8.34 |
More ▼
Balance sheet in USDView more
| Current ratio | 1.26 |
|---|---|
| Quick ratio | 1.10 |
| Total debt/total equity | 1.26 |
|---|---|
| Total debt/total capital | 0.5584 |
More ▼
Growth rates in USD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 2.74% and 23.76%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 3.86% |
|---|---|
| Div growth rate (5 year) | 5.64% |
| Payout ratio (TTM) | 3,083.33% |
| EPS growth(5 years) | 1.53 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -98.20 |
More ▼
